Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) Meeting Abstract
| Authors: | Grob, J. J.; Schadendorf, D.; Wagstaff, J.; Márquez-Rodas, I.; Lebbé, C.; Ascierto, P. A.; Hodi, F. S.; Grossmann, K.; Hassel, J. C.; Walker, D.; Bhore, R.; Larkin, J.; Wolchok, J. D. |
| Abstract Title: | Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx377.009 |
| Language: | English |
| ACCESSION: | WOS:000411324003087 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx377.009 |
| Notes: | Meeting Abstract: 1222PD -- Appears on pages 432-433 of the abstract book -- Source: Wos |
